A Phase 1 Study To Evaluate The Safety, Pharmacokinetics, And Pharmacodynamics Of PF 04449913, An Oral Hedgehog Inhibitor, Administered As Single Agent In Select Hematologic Malignancies

Inclusion Criteria:

- Patients with select advanced hematologic malignancies who are refractory, resistant
or intolerant to prior therapies. They may be newly diagnosed and previously
untreated, but not eligible for standard treatment options, or for whom standard
therapies are not anticipated to result in a durable response.

- ECOG performance status 0 to 2

- Adequate organ function

Exclusion Criteria:

- Patients with active CNS disease

- Patient with active malignancy with the exception of basal cell carcinoma, non
melanoma skin cancer, carcinoma in situ cervical or skin cancer

- Active GVHD other than Grade 1 skin involvement

- Known malabsorption syndrome

- Patient has an active, life threatening or clinically significant uncontrolled
systemic infection